Aminoglycoside therapy in infectious diseases

Bibliography

• Davies J, Wright GD. Bacterial resistance to aminoglycoside antibiotics. Trends Microbiol 1997;5(6):234-40
   PubMed Web of Science ®Google Scholar
• Hamilton-Miller JM, Shah S. Activity of the semi-synthetic kanamycin B derivative, arbekacin against methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 1995;35(6):865-8
   PubMedGoogle Scholar
• Cohen-Kerem R, Kisilevsky V, Einarson TR, et al. Intratympanic gentamicin for Menière's disease: a meta-analysis. Laryngoscope 2004;114(12):2085
   PubMed Web of Science ®Google Scholar
• Wilschanski M, Yahav Y, Yaacov Y, et al. Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. N Engl J Med 2003;349(15):1433-41
   PubMed Web of Science ®Google Scholar
• Malik V, Rodino-Klapac L, Viollet L, Mendell J. Aminoglycoside-induced mutation suppression (stop codon readthrough) as a therapeutic strategy for Duchenne muscular dystrophy. Ther Adv Neurol Disord 2010;3(6):379-89
   PubMedGoogle Scholar
• Durante-Mangoni E, Grammatikos A, Utili R, Falagas ME. Do we still need the aminoglycosides? Int J Antimicrob Agents 2009;33(3):201-5
   PubMed Web of Science ®Google Scholar
• Mingeot-Leclercq MP, Glupczynski Y, Tulkens PM. Aminoglycosides: activity and resistance. Antimicrob Agents Chemother 1999;43(4):727-37
   PubMed Web of Science ®Google Scholar
• Hermann T. Aminoglycoside antibiotics: old drugs and new therapeutic approaches. Cell Mol Life Sci 2007;64(14):1841-52
   PubMed Web of Science ®Google Scholar
• Oliveira JF, Cipullo JP, Burdmann EA. Aminoglycoside nephrotoxicity. Braz J Cardiovasc Surg 2006;21(4):444-52
   Google Scholar
• Lacy MK, Nicolau DP, Nightingale CH, Quintiliani R. The pharmacodynamics of aminoglycosides. Clin Infect Dis 1998;27(1):23-7
   PubMed Web of Science ®Google Scholar
• Karlowsky JA, Zelenitsky SA, Zhanel GG. Aminoglycoside adaptive resistance. Pharmacotherapy 1997;17(3):549-55
   PubMedGoogle Scholar
• Humes HD. Aminoglycoside nephrotoxicity. Kidney Int 1988;33(4):900-11
   PubMed Web of Science ®Google Scholar
• Lopez-Novoa JM, Quiros Y, Vicente L, et al. New insights into the mechanism of aminoglycoside nephrotoxicity: an integrative point of view. Kidney Int 2011;79(1):33-45
   PubMed Web of Science ®Google Scholar
• Levin ML. Aminoglycoside nephrotoxicity: keys to prevention. J Crit Illn 1994;9(10):911-2, 915
   PubMedGoogle Scholar
• Xie J, Talaska AE, Schacht J. New developments in aminoglycoside therapy and ototoxicity. Hear Res 2011;281(1-2):28-37
   PubMed Web of Science ®Google Scholar
• Rybak LP, Ramkumar V. Ototoxicity. Kidney Int 2007;72(8):931-5
   PubMed Web of Science ®Google Scholar
• Usami S, Abe S, Akita J, et al. Prevalence of mitochondrial gene mutations among hearing impaired patients. J Med Genet 2000;37(1):38-40
   PubMed Web of Science ®Google Scholar
• de Jager P, van Altena R. Hearing loss and nephrotoxicity in long-term aminoglycoside treatment in patients with tuberculosis. Int J Tuberc Lung Dis 2002;6(7):622-7
   PubMed Web of Science ®Google Scholar
• Feldman L, Efrati S, Eviatar E, et al. Gentamicin-induced ototoxicity in hemodialysis patients is ameliorated by N-acetylcysteine. J Kidney Int 2007;72(3):359
   PubMedGoogle Scholar
• Chen Y, Huang WG, Zha DJ, et al. Aspirin attenuates gentamicin ototoxicity: from the laboratory to the clinic. Hear Res 2007;226(1-2):178-82
   PubMed Web of Science ®Google Scholar
• Bitner-Glindzicz M, Pembrey M, Duncan A, et al. Prevalence of mitochondrial 1555A–>G mutation in European children. N Engl J Med 2009;360(6):640-2
   PubMed Web of Science ®Google Scholar
• Pasquale TR, Tan JS. Nonantimicrobial effects of antibacterial agents. Clin Infect Dis 2005;40(1):127-35
   PubMedGoogle Scholar
• The Medical Letter. Antimicrobial prophylaxis for surgery. Treat Guide Med Lett 2012;10(122):73-8
   PubMedGoogle Scholar
• Hobbie S N, Kaiser M, Schmidt S, et al. Genetic reconstruction of protozoan rRNA decoding sites provides a rationale for paromomycin activity against leishmania and trypanosoma. PLoS Negl Trop Dis 2011;5(5):e1161
   Google Scholar
• Ben Salah A, Ben Messaoud N, Guedri E, et al. Topical Paromomycin with or without Gentamicin for Cutaneous Leishmaniasis. N Engl J Med 2013;368:524-32
   PubMed Web of Science ®Google Scholar
• Falagas ME, Siempos II, Bliziotis IA, Michalopoulos A. Administration of antibiotics via the respiratory tract for the prevention of ICU-acquired pneumonia: a meta-analysis of comparative trials. Crit Care 2006;10(4):R123
   PubMed Web of Science ®Google Scholar
• Falagas ME, Agrafiotis M, Athanassa Z, Siempos II. Administration of antibiotics via the respiratory tract as monotherapy for pneumonia. Expert Rev Anti Infect Ther 2008;6(4):447-52
   PubMed Web of Science ®Google Scholar
• Ioannidou E, Siempos II, Falagas ME. Administration of antimicrobials via the respiratory tract for the treatment of patients with nosocomial pneumonia: a meta-analysis. J Antimicrob Chemother 2007;60(6):1216-26
   PubMed Web of Science ®Google Scholar
• Michalopoulos A, Metaxas EI, Falagas ME. Aerosol delivery of antimicrobial agents during mechanical ventilation: current practice and perspectives. Curr Drug Deliv 2011;8(2):208-12
   PubMed Web of Science ®Google Scholar
• American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005;171(4):388-416
   PubMed Web of Science ®Google Scholar
• Conway SP. Nebulized antibiotic therapy: the evidence. Chron Respir Dis 2005;2(1):35-41
   PubMedGoogle Scholar
• Barza M, Ioannidis JP, Cappelleri JC, Lau J. Single or multiple daily doses of aminoglycosides: a meta-analysis. BMJ 1996;312(7027):338-45
   PubMed Web of Science ®Google Scholar
• Hatala R, Dinh T, Cook DJ. Once-daily aminoglycoside dosing in immunocompetent adults: a meta-analysis. Ann Intern Med 1996;124(8):717-25
   PubMed Web of Science ®Google Scholar
• Freeman CD, Nicolau DP, Belliveau PP, Nightingale CH. Once-daily dosing of aminoglycosides: review and recommendations for clinical practice. J Antimicrob Chemother 1997;39(6):677-86
   PubMedGoogle Scholar
• Smyth AR, Bhatt J. Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis. Cochrane Database Syst Rev 2012;2:CD002009- doi: 10.1002/14651858
   Google Scholar
• Rao SC, Srinivasjois R, Hagan R, Ahmed M. One dose per day compared to multiple doses per day of gentamicin for treatment of suspected or proven sepsis in neonates. Cochrane Database Syst Rev 2011;11):CD005091
   Google Scholar
• Pérez V, Saénz D, Madriz J, et al. A double-blind study of the efficacy and safety of multiple daily doses of amikacin versus one daily dose for children with perforated appendicitis in Costa Rica. Int J Infect Dis 2011;15(8):e569-75
   Google Scholar
• Best EJ, Gazarian M, Cohn R, et al. Once-daily gentamicin in infants and children: a prospective cohort study evaluating safety and the role of therapeutic drug monitoring in minimizing toxicity. Pediatr Infect Dis J 2011;30(10):827-32
   PubMed Web of Science ®Google Scholar
• Banerjee S, Narayanan M, Gould K. Monitoring aminoglycoside level. BMJ 2012;345:e6354
   PubMed Web of Science ®Google Scholar
• Begg EJ, Barclay ML. Aminoglycosides–50 years on. Br J Clin Pharmacol 1995;39(6):597-603
   PubMed Web of Science ®Google Scholar
• Baddour LM, Wilson WR, Bayer AS, et al. Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease; Council on Cardiovascular Disease in the Young; Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia; American Heart Association; Infectious Diseases Society of America. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation 2005;111(23):e394-434
   Web of Science ®Google Scholar
• Nicolau DP, Freeman CD, Belliveau PP, et al. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob Agents Chemother 1995;39(3):650-5
   PubMed Web of Science ®Google Scholar
• McCormack JP. An emotional-based medicine approach to monitoring once-daily aminoglycosides. Pharmacotherapy 2000;20(12):1524-7
   PubMedGoogle Scholar
• Georghiou SB, Magana M, Garfein RS, et al. Evaluation of genetic mutations associated with mycobacterium tuberculosis resistance to amikacin, kanamycin and capreomycin: a systematic review. PLoS One 2012;7(3):e33275
   PubMed Web of Science ®Google Scholar
• Wachino J, Arakawa Y. Exogenously acquired 16S rRNA methyltransferases found in aminoglycoside-resistant pathogenic Gram-negative bacteria: an update. Drug Resist Updat 2012;15(3):133-48
   PubMedGoogle Scholar
• Vakulenko BS, Mobashery S. Versatility of aminoglycosides and prospects for their future. Clin Microbiol Rev 2003;16(3):430-50
   PubMed Web of Science ®Google Scholar
• Poole K. Aminoglycoside resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2005;49:479-87
   PubMed Web of Science ®Google Scholar
• Pfaller AM, Jones NR, Doern VJ, Kugler K; The Sentry Participants Group. Bacterial pathogens isolated from patients with bloodstream infection: frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (United States and Canada, 1997). Antimicrob Agents Chemother 1998;42(7):1762-70
   PubMed Web of Science ®Google Scholar
• Gonzalez LS III, Spencer JP. Aminoglycosides: a practical review. Am Fam Physician 1998;58(8):1811-20
   PubMed Web of Science ®Google Scholar
• Falagas ME, Karageorgopoulos DE, Georgantzi GG, et al. Susceptibility of Gram-negative bacteria to isepamicin: a systematic review. Expert Rev Anti Infect Ther 2012;10(2):207-18
   PubMed Web of Science ®Google Scholar
• Maraki S, Samonis G, Karageorgopoulos DE, et al. In vitro antimicrobial susceptibility to isepamicin of 6,296 Enterobacteriaceae clinical isolates collected at a tertiary care university hospital in Greece. Antimicrob Agents Chemother 2012;56(6):3067-73
   PubMedGoogle Scholar
• Samonis G, Maraki S, Vouloumanou EK, et al. Antimicrobial susceptibility of non-fermenting Gram-negative isolates to isepamicin in a region with high antibiotic resistance. Eur J Clin Microbiol Infect Dis 2012;31(11):3191-8
   PubMedGoogle Scholar
• Hwang JH, Lee JH, Moon MK, et al. The usefulness of arbekacin compared to vancomycin. Eur J Clin Microbiol Infect Dis 2012;31(7):1663-6
   PubMedGoogle Scholar
• Daniels M, Hill AB. Chemotherapy of pulmonary tuberculosis in young adults. Br Med J 1952;1(4769):1162-8
   PubMed Web of Science ®Google Scholar
• Falzon D, Jaramillo E, Schünemann HJ, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 2011;38:516-28
   PubMed Web of Science ®Google Scholar
• Inglesby TV, Dennis DT, Henderson DA, et al. Plague as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA 2000;283(17):2281-90
   PubMed Web of Science ®Google Scholar
• Infectious Diseases Society of America. Tularemia: current, comprehensive information on pathogenesis, microbiology, epidemiology, diagnosis, treatment, and prophylaxis. Available from: http://biodefense.idsociety.org/idsa/bt/tularemia/biofacts/tularemiafactsheet.html#_References_3) [Accessed 8 March 2013]
   Google Scholar
• Yousefi-Nooraie R, Mortaz-Hejri S, Mehrani M, Sadeghipour P. Antibiotics for treating human brucellosis. Cochrane Database Syst Rev 2012;10:CD007179- doi: 10.1002/14651858
   PubMedGoogle Scholar
• Rolain JM, Brouqui P, Koehler JE, et al. Recommendations for Treatment of Human Infections Caused by Bartonella Species. Antimicrob Agents Chemother 2004;48(6):1921-33
   PubMed Web of Science ®Google Scholar
• Quagliarello VJ, Scheld WM. Treatment of bacterial meningitis. Engl J Med 1997;336(10):708
   PubMed Web of Science ®Google Scholar
• Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 2004;39(9):1267-84
   PubMed Web of Science ®Google Scholar
• Murray B E. The life and times of the Enterococcus. Clin Microbiol Rev 1990;3(1):46-65
   PubMedGoogle Scholar
• Lorber B. Listeriosis. Clin Infect Dis 1997;24(1):1-9
   PubMed Web of Science ®Google Scholar
• Pintado V, Cabellos C, Moreno S, et al. Enterococcal meningitis: a clinical study of 39 cases and review of the literature. Medicine (Baltimore) 2003;82(5):346-64
   PubMed Web of Science ®Google Scholar
• Falagas ME, Matthaiou DK, Bliziotis IA. The role of aminoglycosides in combination with a beta-lactam for the treatment of bacterial endocarditis: a meta-analysis of comparative trials. J Antimicrob Chemother 2006;57(4):639-47
   PubMedGoogle Scholar
• Cosgrove SE, Vigliani GA, Fowler VG Jr, et al. Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic. Clin Infect Dis 2009;48(6):713-21
   PubMed Web of Science ®Google Scholar
• Safdar N, Handelsman J, Maki DG. Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis. Lancet Infect Dis 2004;4(8):519-27
   PubMed Web of Science ®Google Scholar
• Paul M, Leibovici L. Combination antibiotic therapy for Pseudomonas aeruginosa bacteraemia. Lancet Infect Dis 2005;5(4):192-3
   PubMedGoogle Scholar
• Bliziotis IA, Samonis G, Vardakas KZ, et al. Effect of aminoglycoside and beta-lactam combination therapy versus beta-lactam monotherapy on the emergence of antimicrobial resistance: a meta-analysis of randomized, controlled trials. Clin Infect Dis 2005;41(2):149-58
   PubMed Web of Science ®Google Scholar
• Bliziotis IA, Petrosillo N, Michalopoulos A, et al. Impact of definitive therapy with beta-lactam monotherapy or combination with an aminoglycoside or a quinolone for Pseudomonas aeruginosa bacteremia. PLoS One 2011;6(10):e26470
   Google Scholar
• Chatzinikolaou I, Abi-Said D, Bodey GP, et al. Recent experience with Pseudomonas aeruginosa bacteremia in patients with cancer: retrospective analysis of 245 episodes. Arch Intern Med 2000;160(4):501-9
   PubMedGoogle Scholar
• van Delden C. Pseudomonas aeruginosa bloodstream infections: how should we treat them? Int J Antimicrob Agents 2007;30(Suppl 1):S71-5
   Google Scholar
• Leibovici L, Vidal L, Paul M. Aminoglycoside drugs in clinical practice: an evidence-based approach. J Antimicrob Chemother 2009;63(2):246-51
   PubMed Web of Science ®Google Scholar
• Paul M, Silbiger I, Grozinsky S, et al. Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis. Cochrane Database Syst Rev 2006;(1):CD003344
   Google Scholar
• Kang CI, Kim SH, Park WB, et al. Bloodstream infections caused by antibiotic-resistant gram-negative bacilli: risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcome. Antimicrob Agents Chemother 2005;49(2):760-6
   PubMed Web of Science ®Google Scholar
• Micek ST, Welch EC, Khan J, et al. Resistance to empiric antimicrobial treatment predicts outcome in severe sepsis associated with Gram-negative bacteremia. J Hosp Med 2011;6(7):405-10
   PubMedGoogle Scholar
• Micek ST, Welch EC, Khan J, et al. Empiric combination antibiotic therapy is associated with improved outcome against sepsis due to Gram-negative bacteria: a retrospective analysis. Antimicrob Agents Chemother 2010;54(5):1742-8
   PubMed Web of Science ®Google Scholar
• Zilberberg MD, Shorr AF, Micek ST, et al. Antimicrobial therapy escalation and hospital mortality among patients with health-care-associated pneumonia: a single-center experience. Chest 2008;134(5):963-8
   PubMedGoogle Scholar
• Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America; American Thoracic Society. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44(Suppl 2):S27-72
   PubMed Web of Science ®Google Scholar
• Bailey JA, Virgo KS, DiPiro JT, et al. Aminoglycosides for intra-abdominal infection: equal to the challenge? Surg Infect (Larchmt) 2002;3(4):315-35
   PubMedGoogle Scholar
• Falagas ME, Matthaiou DK, Karveli EA, Peppas G. Meta-analysis: randomized controlled trials of clindamycin/aminoglycoside vs. beta-lactam monotherapy for the treatment of intra-abdominal infections. Aliment Pharmacol Ther 2007;25(5):537-56
   PubMedGoogle Scholar
• Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis 2010;50(2):133-64
   PubMed Web of Science ®Google Scholar
• Wood MJ, Farrell W. Comparison of urinary excretion of tobramycin and gentamicin in adults. J Infect Dis 1976;134(Suppl):S133-6
   Google Scholar
• Vidal L, Gafter-Gvili A, Borok S, et al. Efficacy and safety of aminoglycoside monotherapy: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother 2007;60(2):247-57
   PubMed Web of Science ®Google Scholar
• Satlin MJ, Kubin CJ, Blumenthal JS, et al. Comparative effectiveness of aminoglycosides, polymyxin B, and tigecycline for clearance of carbapenem-resistant Klebsiella pneumoniae from urine. Antimicrob Agents Chemother 2011;55(12):5893-9
   PubMed Web of Science ®Google Scholar
• Gupta K, Hooton TM, Naber KG, et al. Infectious Diseases Society of America; European Society for Microbiology and Infectious Diseases. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 2011;52(5):e103-20
   PubMed Web of Science ®Google Scholar
• Badal R, Lob S, Bouchillon S, et al. Global trends in frequency and susceptibility of extended-spectrum β-lactamase positive E. coli, K. Pneumoniae, and K. oxytoca isolated from intra-abdominal infections since 2005 – the SMART Study [Poster 1179]. Presented at: The 22nd European Congress of Clinical Microbiology and Infectious Diseases; 31 March – 3 April 2012; London, UK
   Google Scholar
• Gales AC, Jones RN, Sader HS. Global assessment of the antimicrobial activity of polymyxin B against 54 731 clinical isolates of Gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001-2004). Clin Microbiol Infect 2006;12(4):315-21
   PubMed Web of Science ®Google Scholar
• Miller GH, Sabatelli FJ, Hare RS, et al. The most frequent aminoglycoside resistance mechanisms–changes with time and geographic area: a reflection of aminoglycoside usage patterns? Aminoglycoside Resistance Study Groups. Clin Infect Dis 1997;24(Suppl 1):S46-62
   PubMed Web of Science ®Google Scholar
• Livermore DM, Mushtaq S, Warner M, et al. Activity of aminoglycosides, including ACHN-490, against carbapenem resistant Enterobacteriaceae isolates. JAC 2011;66:48-53
   Google Scholar
• Zapor MJ, Barber M, Summers A, et al. In vitro activity of the aminoglycoside antibiotic arbekacin against acinetobacter baumannii-calcoaceticus isolated from war-wounded patients at walter reed army medical center. Antimicrob Agents Chemother 2010;54(7):3015-17
   PubMedGoogle Scholar
• Bush K. Improving known classes of antibiotics: an optimistic approach for the future. Curr Opin Pharmacol 2012;12(5):527-34
   PubMed Web of Science ®Google Scholar
• Cass RT, Brooks CD, Havrilla NA, et al. Pharmacokinetics and safety of single and multiple doses of ACHN-490 injection administered intravenously in healthy subjects. Antimicrob Agents Chemother 2011;55(12):5874-80
   PubMed Web of Science ®Google Scholar
• Study for the treatment of complicated urinary tract infection and acute pyelonephritis. Available from: http:/clinicaltrials.gov/ct2/show/NCT01096849
   Google Scholar
• Landman D, Kelly P, Bäcker M, et al. Antimicrobial activity of a novel aminoglycoside, ACHN-490, against Acinetobacter baumannii and Pseudomonas aeruginosa from New York City. J Antimicrob Chemother 2011;66(2):332-4
   PubMed Web of Science ®Google Scholar
• Endimiani A, Hujer KM, Hujer AM, et al. ACHN-490, a neoglycoside with potent in vitro activity against multidrug-resistant Klebsiella pneumoniae isolates. Antimicrob Agents Chemother 2009;53(10):4504-7
   PubMed Web of Science ®Google Scholar
• Galani I, Souli M, Daikos GL, et al. Activity of plazomicin (ACHN-490) against MDR clinical isolates of Klebsiella pneumoniae, Escherichia coli, and Enterobacter spp. from Athens, Greece. J Chemother 2012;24(4):191-4
   PubMed Web of Science ®Google Scholar
• Reyes N, Aggen JB, Kostrub CF. In vivo efficacy of the novel aminoglycoside ACHN-490 in murine infection models. Antimicrob Agents Chemother 2011;55(4):1728-33
   PubMed Web of Science ®Google Scholar
• Lin G, Ednie LM, Appelbaum PC. Antistaphylococcal activity of ACHN-490 tested alone and in combination with other agents by time-kill assay. Antimicrob Agents Chemother 2010;54(5):2258-61
   PubMed Web of Science ®Google Scholar
• Ramirez MS, Tolmasky ME. Aminoglycoside modifying enzymes. Drug Resist Updat 2010;13(6):151-71
   PubMed Web of Science ®Google Scholar